JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure
$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...
445 Views
Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China
We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...
528 Views
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
516 Views
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
570 Views
China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
425 Views